Clinical Trial Update: Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only [Phase 3]

View source ↗

Summary

Phase 3 open-label extension updates for skeletal-related events in patients with bone metastases from prostate cancer and breast cancer (and other cancers); re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Multiple Myeloma
• Prostate Cancer

Snippet

Sponsor: Amgen | Conditions: Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-02-11